Vis børsmeldingen
subscription price of NOK 26, to settle an amount of EUR 500,000 of an already
triggered option exercise fee towards Inven2. The Company’s Board of Directors
has today resolved to issue 227,096 new shares in the Company to Inven2 against
set-off of such amount of EUR 500,000.
After the share capital increase related to the issuance of the new shares has
been registered with the Norwegian Register of Business Enterprises, the Company
will have a share capital of NOK 20,454,162, divided into 20,454,162 shares,
each with a par value of NOK 1.
For further information, please contact:
Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632
About Zelluna ASA
Zelluna’s mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of “off the
shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used “off
the shelf” to overcome scaling limitations of current cell therapies. The lead
program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.
Kilde
